Shots:

• GSK has licensed its M72/AS01_E to the Gates MRI for further development and potential use of vaccine therapy in low-income countries with high TB burdens
• Under the agreement- the GATES MRI will lead the development program and will be responsible to sponsor future clinical studies while GSK will provide the AS01 adjuvant for the development program
• GSK’s M72/AS01_E consist of M72 recombinant fusion protein- derived from two Mycobacterium tuberculosis antigens (Mtb32A and Mtb39A)- combined with the adjuvant system AS01

Click here ­to­ read full press release/ article 

Ref: GSK | Image: GSK